CCDC135 Inhibitors

Wortmannin and LY294002 are inhibitors of PI3K, an upstream regulator of the AKT signaling pathway, affecting numerous cellular processes, including those that may involve CCDC135. Rapamycin and Torin 1 target the mTOR pathway, which plays a central role in controlling cell growth and proliferation. These inhibitors can have profound effects on cellular processes, potentially intersecting with any roles that CCDC135 may have in these pathways. PD98059 and U0126, which inhibit the MEK1/2 enzymes, along with SB203580, targeting p38 MAPK, and SP600125, targeting JNK, are all involved in the MAPK/ERK pathway, a critical regulator of cell division, differentiation, and response to stress signals.

Additional compounds like Gefitinib and Imatinib inhibit specific tyrosine kinases associated with growth factor signaling, thereby possibly influencing signaling pathways that intersect with CCDC135's function. Triciribine is an AKT inhibitor, which by modulating AKT signaling, may affect processes where CCDC135 is involved. ZM447439 targets Aurora kinases that play key roles in mitotic progression, which can lead to alterations in cellular processes potentially involving CCDC135.